Skip to main content
    A

    Amgen Inc (AMGN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $462.32
    -3.35 (-0.72%)

    Market Cap: $251.89B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Amgen Inc (AMGN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Amgen (AMGN) to earn $23.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $39.48B. Of 34 analysts, 12 rate the stock Buy or Strong Buy, 17 Hold and 5 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 25 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 34 ratings average 2.74, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 35% of the ratings.

    RatingAnalystsShare
    Strong Buy411.8%
    Buy823.5%
    Hold1750.0%
    Sell38.8%
    Strong Sell25.9%
    Consensus
    Hold
    Total analysts
    34

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 6.4% and revenue estimates rise 4.6%.

    Fiscal year ending Dec 31, 2026
    $23.53
    EPS consensus, revenue $39.48B
    Fiscal year ending Dec 31, 2027
    $25.04
    EPS consensus, revenue $41.29B
    Next report
    Feb 1, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$23.53$22.97 to $25.7932$39.48B$38.88B to $39.73B29
    Dec 31, 2027$25.04$23.52 to $26.5632$41.29B$40.04B to $44.46B30

    Quarterly Estimates

    The EPS consensus falls from $5.72 for the quarter ending Dec 31, 2026 to $5.70 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$5.72$5.03 to $6.3830$10.69B$10.00B to $11.31B28
    Mar 31, 2027$5.70$5.13 to $6.0910$9.48B$8.78B to $10.07B7

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 45 upward and 9 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2026252
    Fiscal year ending Dec 31, 2027175
    Quarter ending Mar 31, 202732

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.3% from $22.99.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$23.53$23.50$23.01$23.04$22.99+2.4%
    Fiscal year ending Dec 31, 2027$25.04$24.99$24.51$24.40$24.28+3.1%
    Quarter ending Mar 31, 2027$5.70$5.69$5.61$5.60$5.59+1.9%

    Frequently Asked Questions About AMGN

    What is the AMGN stock forecast?

    Consensus analyst estimates put Amgen's EPS at $23.53 for the fiscal year ending Dec 31, 2026, on revenue of $39.48B. The consensus rating from 34 analysts is Hold.

    How do analysts rate AMGN stock?

    Of 34 analysts covering Amgen, 4 rate it Strong Buy, 8 Buy, 17 Hold, 3 Sell and 2 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from AMGN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $23.53, with estimates from $22.97 to $25.79 from 32 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $25.04, with estimates from $23.52 to $26.56 from 32 analysts.

    What revenue do analysts expect from Amgen next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $39.48B, with estimates from $38.88B to $39.73B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $41.29B, with estimates from $40.04B to $44.46B.

    How many analysts cover AMGN?

    34 analysts rate Amgen stock, and 32 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.